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Abstract
Background Serous cystic neoplasms of the pancreas are benign lesions with little chance for malignant degeneration. We
report a case of malignant serous cystadenocarcinoma of the pancreas and review the literature.
Methods Structured review of the literature was performed using PubMed and MEDLINE searches, and cases of serous
cystadenocarcinoma of the pancreas were compiled.
Results A 70-year-old man diagnosed with a serous cystadenoma was managed expectantly until he became symptomatic,
and studies revealed an increase in the size of the lesion as well as duodenal invasion. The patient underwent a
pancreaticoduodenectomy, and histopathological examination revealed a locally invasive cystadenocarcinoma without
metastatic disease. Seven years later, the patient remains disease-free. Review of the literature identified 25 cases of serous
cystadenocarcinoma published to date. The mean age at diagnosis is 68±2 years (range, 52 to 81), and women are affected
more commonly (2:1).
Conclusions We conclude that there is a small but finite risk of malignancy for serous cystic neoplasms of the pancreas. The
clinician should bear this in mind when faced with decisions regarding patient management. Prognosis is excellent with
multiple reports of long-term survival even in the face of metastatic disease.
Keywords Pancreas.Oncology.Serouscysticlesion.
Serouscystadenoma.Serouscystadenocarcinoma
Introduction
Malignant cystic neoplasms are rare entities that account for
only 1% of all pancreatic tumors.
1 Serous and mucinous
cystic neoplasms are tumors of the exocrine pancreas with
different biological behaviors. Mucinous cystic tumors are
typically slow-growing but carry a significant potential for
malignancy, and thus, resection is often indicated.
2,3 In
contrast, serous cystadenomas are considered benign tumors
with almost no malignant potential. They are often observed
with serial imaging or managed expectantly.
4 In the absence
of symptoms, surgery is not usually recommended.
The first case of a pancreatic serous cystadenocarcinoma
was reported by George et al. in 1989. The authors
described the malignant characteristics of a serous cystic
tumor of the pancreas with invasion into the spleen,
stomach, and liver. The patient expired intra-operatively
due to hemorrhage.
5 Subsequently, additional reports have
documented similar findings of serous cystic neoplasms
with malignant behavior. The histological characteristics of
serous cystadenocarcinoma are indistinguishable from its
benign counterpart, making the presence of invasion the
sole distinguishing characteristic between the two.
5 In this
report, we present a case of serous cystadenocarcinoma
with duodenal, vascular, and neural invasion. We also
J Gastrointest Surg (2009) 13:1864–1868
DOI 10.1007/s11605-009-0926-3
J. C. King: T. T. Ng:S. C. White: H. A. Reber: O. J. Hines (*)
Department of Surgery,
David Geffen School of Medicine at UCLA,
Box 956904, 72-170 CHS,
Los Angeles, CA 90095-6904, USA
e-mail: joehines@mednet.ucla.edu
G. Cortina
Department of Pathology,
David Geffen School of Medicine at UCLA,
Los Angeles, CA, USAreview the literature and discuss the current diagnostic
techniques and principles of management.
Materials and Methods
A systematic review of the literature was performed utilizing
PubMed and MEDLINE searches. Articles were identified
using the search terms: pancreas and serous cystadenocarci-
noma. Nineteen articles were included in the analysis. Data
are presented as mean±standard error of the mean.
Results
A 70-year-old man presented with upper gastrointestinal
(GI) bleeding and abdominal pain. There was a duodenal
ulcer with no evidence of malignancy on esophagogastro-
duodenoscopy (EGD), and an abdominal computed tomog-
raphy (CT) scan revealed a 5.7-cm cystic mass in the head
of the pancreas which was diagnosed by core needle biopsy
as a serous cystadenoma. The patient was treated for
presumed duodenal ulcer disease leading to resolution of
symptoms and scheduled for observation of his pancreatic
mass.
Three months later, the patient returned with recurrent
coffee-ground emesis and abdominal pain. CT scan showed
enlargement of the pancreatic mass to 6.5×8 cm and central
dystrophic calcifications with new pancreatic and biliary
ductal dilatation (Fig. 1). Repeat EGD identified a bleeding
duodenal ulceration, and biopsies were consistent with a
“benign” serous cystadenoma.
Upon surgical consultation, an elective pancreaticoduo-
denectomy was planned due to the increased size of the
tumor, recurrent bleeding, and erosion into the duodenum.
Laparotomy revealed a large mass in the head of the
pancreas with no evidence of gross metastatic disease or
invasion of the mesenteric vessels. The patient’s post-
operative course was complicated by delayed gastric
emptying requiring temporary gastrostomy and feeding
jejunostomy tubes.
On gross examination, the mass measured 9×8×6 cm,
and there was marked, aggressive invasion of the duode-
num beyond the level of the muscularis propria (Fig. 2).
Histology demonstrated microcysts lined by clear cells
without mucinous cytoplasm (Fig. 3). Microscopic vascular
and perineural invasion were also seen, further distinguish-
ing this lesion from a benign serous cystadenoma (Figs. 4
and 5). All resection margins and 17 lymph nodes were
uninvolved.
Immunochemical stains for keratin AE1/3, 7, and 19 and
CAM 5.2 were positive. Stained samples of the mass also
showed weak immunoreactivity for carcinoembryonic anti-
gen (CEA). Keratin 20 staining was negative. DNA content
analysis by flow cytometry demonstrated no evidence of
aneuploidy.
The final diagnosis was serous cystadenocarcinoma with
duodenal, vascular, and neural invasion. At last follow-up
7 years post-operatively, the patient is doing well without
clinical or radiographic evidence of recurrent disease.
Literature review yielded 25 reports of serous cystade-
nocarcinoma (Table 1).
5–23 The average age at presentation
is 68±2 years, and 60% of patients affected are female
(28% male; in 12% of cases, sex was not reported).
Presenting complaints included abdominal pain (24%),
upper GI bleeding (12%), weight loss (8%), palpable mass
(8%), jaundice or abnormal serum liver enzymes (8%), and
nonspecific abdominal complaints (8%).
Fig. 1 Contrast-enhanced CT scan demonstrating a large mass
measuring 6.5×8 cm in the head of the pancreas (arrow) with central
dystrophic calcifications.
Fig. 2 Gross appearance of the tumor. Note invasion of the
duodenum through the muscularis propria and submucosa with
ulceration of the overlying mucosa (arrow).
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10±1 cm (range, 2.5–19 cm). Lesions exhibit both of the
hallmarks of malignancy: local invasiveness and distant
metastasis with most tumors associated with local invasion
of the spleen (8%), small intestine (4%), stomach (4%),
adrenal gland (4%), or microscopic invasion of vascular
and neural tissues. Synchronous or metachronous liver
metastases were frequently noted (36%), along with
metastasis to regional lymph nodes (12%), bone marrow
(4%), and lung (4%). Mean survival was 36±11 months
(range, <30 days to 120 months) among cases with follow-
up (n=11), and ten (91%) of these patients were still alive
when reports were published including seven (64%)
patients with metastatic disease.
Discussion
The preoperative differentiation between a benign serous
cystadenoma and malignant serous cystadenocarcinoma
remains difficult. Indeed, the correct diagnosis of serous
cystadenocarcinoma was not made pre-operatively in any of
the cases, including the current one.
5–23 The benign and
malignant variants appear identical histologically, with the
only distinguishing feature being gross or microscopic
evidence of invasiveness. Thus, the utility of cytology or
histology obtained from core needle biopsy is limited.
18
The current practice for management of serous cystadeno-
mas of the pancreas is to observe asymptomatic lesions
thereby avoiding the potential morbidity and mortality
associated with a major operation.
13,14,18,24,25 We agree with
this conservative approach. Nevertheless, clinicians should be
aware of the possibility for malignant transformation in
serous cystic neoplasms and should maintain an index of
suspicion when certain clues appear. These include the onset
of new symptoms, worsening of symptoms, or rapid enlarge-
ment of the mass. In these cases, resection may be indicated,
despite the lack of objective evidence for malignancy ob-
tained from preoperative imaging, endoscopy, and biopsies.
In the current case, a serous cystadenocarcinoma was
diagnosed without evidence of distant metastasis but with
extensive tumor invasion into surrounding structures, both
grossly and microscopically. To our knowledge, this is the
first example of serous cystadenocarcinoma with extensive
duodenal, vascular, and neural invasion but no distant
metastases.
Conclusion
Our case report is illustrative of the management strategy
for serous cystic lesions of the pancreas despite the
Fig. 4 Vascular invasion. Tumor erodes through the lumen of the
vessel (arrow). Red blood cells and hemosiderin (double arrow) are
present.
Fig. 5 Neural invasion. Tumor cells are noted within the nerve sheath
(arrows).
Fig. 3 Microscopic appearance of the tumor. The tumor is composed
of multiple cysts lined by cuboidal cells with clear cytoplasm.
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J Gastrointest Surg (2009) 13:1864–1868 1867presence of an initially unrecognized malignancy: the
progression of symptoms and increase in size of the mass
triggered curative resection. The excellent prognosis asso-
ciated with serous cystadenocarcinoma justifies an aggres-
sive approach to surgical resection, even in older patients.
This is especially so since major pancreatic resections are
now done with very low mortality and morbidity rates in
major centers around the world.
26
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Becker WF, Welsh A, Pratt HS. Cystadenoma and cystadenocar-
cinoma of the pancreas. Ann Surg 1965;161:845–860.
doi:10.1097/00000658-196506000-00005.
2. Klöppel G, Solcia E, Longnecker DS, Capella C, Sobin LH.
Histological typing of tumors of the exocrine pancreas, 2nd
edition. WHO international histological classification of tumors.
Berlin: Springer, 1996.
3. Compagno J, Oertel JE. Mucinous cystic neoplasms of the
pancreas with overt and latent malignancy (cystadenocarcinoma
and cystadenoma): A clinicopathological study of 41 cases. Am J
Clin Pathol 1978;69:573–580.
4. Compagno J, Oertel JE. Microcystic adenomas of the pancreas
(glycogen-rich cystadenomas). Am J Clin Pathol 1978;69:289–
298.
5. George DH, Murphy F, Michalski R, Ulmer BG. Serous
cystadenocarcinoma of the pancreas: A new entity? Am J Surg
Pathol 1989;13:61–66. doi:10.1097/00000478-198901000-
00009.
6. Friedmann HD. Nonmucinous, glycogen-poor cystadenocarci-
noma of the pancreas. Arch Pathol Lab Med 1990;114:888–891.
7. Kamei K, Funabiki T, Ochiai M, Amano H, Kasahara M,
Sakamoto T. Multifocal pancreatic serous cystadenoma with
atypical cells and focal perineural invasion. Int J Pancreatol
1991;10:161–172.
8. Okada T, Nonami T, Miwa T, Yamada F, Ando K, Tatematsu A,
Sugie S, Kondo T. Hepatic metastasis of serous cystadenocarci-
noma resected 4 years after operation of the primary tumor: A
case report. Jpn J Gastroenterol 1991;88:2719–2723.
9. Yoshimi N, Sugie S, Tanaka T, Aijin W, Bunai Y, Tatematsu O,
Mori H. A rare case of cystadenocarcinoma of the pancreas.
Cancer 1992;69:2449–2453. doi:10.1002/1097-0142(19920515)
69:10<2449::AID-CNCR2820691011>3.0.CO;2-9.
10. Ohta T, Nagakawa T, Itho H, Fonseca L, Miyazaki I, Terada T. A
case of serous cystadenoma of the pancreas with focal malignant
changes. Int J Pancreatol 1993;14:283–289.
11. Widmaier U, Mattfeldt T, Siech M. Serous cystadenocarcinoma of
the pancreas. Int J Pancreatol 1996;20:135–139.
12. Ishikawa T, Nakao A, Nomoto S. Immunohistochemical and
molecular biological studies of serous cystadenoma of the
pancreas. Pancreas 1998;16:40–44. doi:10.1097/00006676-
199801000-00007.
13. Siech M, Tripp K, Schmidt-Rohlfing B, Mattfeldt T, Widmaier U,
Gansauge F, Görich J, Beger HG. Cystic tumors of the pancreas:
Diagnostic accuracy, pathologic observations and surgical con-
sequences. Langenbecks Arch Surg 1998;383:56–61. doi:10.1007/
s004230050092.
14. Eriguchi N, Aoyagi S, Nakayama T, Hara M, Miyazaki T, Kutami
R, Jimi A. Serous cystadenocarcinoma of the pancreas with liver
metastases. J Hepatobiliary Pancreat Surg 1998;5:467–470.
doi:10.1007/s005340050075.
15. Abe H, Kubota K, Mori M, Miki K, Minagawa M, Noie T,
Kimura W, Makuuchi M. Serous cystadenoma of the pancreas
with invasive growth: Benign or malignant? Am J Gastroenterol
1998;93:1963–1966. doi:10.1111/j.1572-0241.1998.00556.x.
16. Schmidt-Rohlfing B, Siech M, Mattfeldt T, Schoenberg MH,
Beger HG. Cystic neoplasms of the pancreas: Surgical treatment
and outcome. Z Gastroenterol 1998;36:939–945.
17. Kimura W, Makuuchi M. Operative indications for cystic lesions
of the pancreas with malignant potential: Our experience.
Hepatogastroenterology 1999;46:483–491.
18. Horvath K, Charbot JA. An aggressive resectional approach to
cystic neoplasms of the pancreas. Am J Surg 1999;178:262–274.
doi:10.1016/S0002-9610(99)00186-5.
19. Wu CM, Fisherman EK, Hruban RK. Serous cystic neoplasm
involving the pancreas and liver: An unusual clinical entity.
Abdom Imaging 1999;24:75–77. doi:10.1007/s002619900445.
20. Strobel O, Z’graggen K, Schmitz-Winnenthal FH, Friess H,
Kappeler A, Zimmermann A, Uhl W, Büchler MW. Risk of
malignancy in serous cystic neoplasms of the pancreas. Digestion
2003;68:24–33. doi:10.1159/000073222.
21. Friebe V, Keck T, Mattern D, Schmitt-Graeff A, Werner M,
Mikami Y, Adam U, Hopt UT. Serous cystadenocarcinoma of the
pancreas: Management of a rare entity. Pancreas 2005;31:182–
187. doi:10.1097/01.mpa.0000167001.89018.3c.
22. Shintaku M, Arimoto A, Sakita N. Serous cystadenocarcinoma of
the pancreas. Pathol Int 2005;55:436–439. doi:10.1111/j.1440-
1827.2005.01850.x.
23. Galanis C, Zamani A, Cameron JL, Campbell KA, Lillemoe KD,
Caparrelli D, Chang D, Hruban RH, Yeo CJ. Resected serous
cystic neoplasms of the pancreas: A review of 158 patients with
recommendations for treatment. J Gastrointest Surg 2007;11:820–
826. doi:10.1007/s11605-007-0157-4.
24. Omeroglu A, Paner GP, Ciesla MC, Hartman G. Serous micro-
cystic adenoma of the pancreas. Arch Pathol Lab Med
2001;125:1613–1614.
25. Tseng JF, Warshaw AL, Sahani DV, Lauwers GY, Rattner DW,
Fernandez-del Castillo C. Serous cystadenoma of the pancreas:
Tumor growth rates and recommendations for treatment. Ann
Surg 2005;242:413–421.
26. Kazanjian KK, Hines OJ, Duffy JP, Yoon DY, Cortina G, Reber
HA. Improved survival following pancreaticoduodenectomy to
treat adenocarcinoma of the pancreas: The influence of operative
blood loss. Arch Surg 2008;14:1166–1171.
1868 J Gastrointest Surg (2009) 13:1864–1868